← Repligen overview

Repligen vs Avantor: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Repligen Corporation (RGEN)

Q3 2026
▲3

Repligen Buys BioLife, Beats Q2, Raises Guidance

  • Repligen to acquire BioLife Solutions for $1.5B Repligen agreed to buy BioLife Solutions for about $1.5 billion in cash and stock. The deal is expected to boost revenue growth, profit margins, and earnings per share, with $20–30 million in cost savings. This signals growth and makes the company more valuable.

    This is the biggest new event driving RGEN's price, showing a major growth move.

  • Q2 revenue beats estimates, full-year guidance raised Repligen reported Q2 revenue of $204.1 million, beating expectations, and adjusted EPS of $0.54, a 20% beat. The company raised full-year revenue and EPS guidance. Organic growth accelerated to 13%. This shows the business is performing better than expected, pushing the stock up.

    This is a fresh, positive earnings surprise that directly lifts investor confidence and the stock price.

  • Biotech stocks hit 52-week highs on deal news Several biotech stocks reached 52-week highs, helped by Repligen's BioLife acquisition announcement. BioLife shares jumped over 6%. This positive sector sentiment can lift Repligen's stock as investors see strength in the industry.

    It shows the acquisition is part of a broader positive trend, reinforcing the stock's upward move.

  • Trump announces phased tariffs on generic drug imports President Trump announced tariffs on generic drug imports, starting at zero for two years, then rising to 100% in 2028 and 200% in 2029. This could raise costs for biopharma companies and disrupt supply chains, but may also encourage onshore manufacturing, which could benefit Repligen's bioprocessing business.

    This is a new policy risk that could affect Repligen's customers and demand, creating uncertainty.

July 2026
▲3

Repligen Buys BioLife, Beats Q2, Raises Guidance

  • Repligen to acquire BioLife Solutions for $1.5B Repligen agreed to buy BioLife Solutions for about $1.5 billion in cash and stock. The deal is expected to boost revenue growth, profit margins, and earnings per share, with $20–30 million in cost savings. This signals growth and makes the company more valuable.

    This is the biggest new event driving RGEN's price, showing a major growth move.

  • Q2 revenue beats estimates, full-year guidance raised Repligen reported Q2 revenue of $204.1 million, beating expectations, and adjusted EPS of $0.54, a 20% beat. The company raised full-year revenue and EPS guidance. Organic growth accelerated to 13%. This shows the business is performing better than expected, pushing the stock up.

    This is a fresh, positive earnings surprise that directly lifts investor confidence and the stock price.

  • Biotech stocks hit 52-week highs on deal news Several biotech stocks reached 52-week highs, helped by Repligen's BioLife acquisition announcement. BioLife shares jumped over 6%. This positive sector sentiment can lift Repligen's stock as investors see strength in the industry.

    It shows the acquisition is part of a broader positive trend, reinforcing the stock's upward move.

  • Trump announces phased tariffs on generic drug imports President Trump announced tariffs on generic drug imports, starting at zero for two years, then rising to 100% in 2028 and 200% in 2029. This could raise costs for biopharma companies and disrupt supply chains, but may also encourage onshore manufacturing, which could benefit Repligen's bioprocessing business.

    This is a new policy risk that could affect Repligen's customers and demand, creating uncertainty.

Latest
▲3

Repligen Buys BioLife, Beats Q2, Raises Guidance

  • Repligen to acquire BioLife Solutions for $1.5B Repligen agreed to buy BioLife Solutions for about $1.5 billion in cash and stock. The deal is expected to boost revenue growth, profit margins, and earnings per share, with $20–30 million in cost savings. This signals growth and makes the company more valuable.

    This is the biggest new event driving RGEN's price, showing a major growth move.

  • Q2 revenue beats estimates, full-year guidance raised Repligen reported Q2 revenue of $204.1 million, beating expectations, and adjusted EPS of $0.54, a 20% beat. The company raised full-year revenue and EPS guidance. Organic growth accelerated to 13%. This shows the business is performing better than expected, pushing the stock up.

    This is a fresh, positive earnings surprise that directly lifts investor confidence and the stock price.

  • Biotech stocks hit 52-week highs on deal news Several biotech stocks reached 52-week highs, helped by Repligen's BioLife acquisition announcement. BioLife shares jumped over 6%. This positive sector sentiment can lift Repligen's stock as investors see strength in the industry.

    It shows the acquisition is part of a broader positive trend, reinforcing the stock's upward move.

  • Trump announces phased tariffs on generic drug imports President Trump announced tariffs on generic drug imports, starting at zero for two years, then rising to 100% in 2028 and 200% in 2029. This could raise costs for biopharma companies and disrupt supply chains, but may also encourage onshore manufacturing, which could benefit Repligen's bioprocessing business.

    This is a new policy risk that could affect Repligen's customers and demand, creating uncertainty.

Avantor Inc (AVTR)

Q3 2026
▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

  • Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.

    The guidance raise and beat are the core new event that changed the growth story.

  • Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.

    Order growth and book-to-bill are the forward-looking evidence behind the recovery.

  • APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.

    A concrete new market expansion that supports future demand.

  • Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.

    The main counterweight: profits are still squeezed even as revenue stabilizes.

August 2026
▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

  • Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.

    The guidance raise and beat are the core new event that changed the growth story.

  • Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.

    Order growth and book-to-bill are the forward-looking evidence behind the recovery.

  • APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.

    A concrete new market expansion that supports future demand.

  • Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.

    The main counterweight: profits are still squeezed even as revenue stabilizes.

Latest
▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

  • Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.

    The guidance raise and beat are the core new event that changed the growth story.

  • Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.

    Order growth and book-to-bill are the forward-looking evidence behind the recovery.

  • APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.

    A concrete new market expansion that supports future demand.

  • Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.

    The main counterweight: profits are still squeezed even as revenue stabilizes.